Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd., a leading player in the pharmaceutical and healthcare industry, is headquartered in Beijing, China. Founded in 1998, the company has established itself as a pivotal force in the distribution of pharmaceuticals, medical devices, and healthcare services across various regions, including Asia, Europe, and Africa. With a diverse portfolio that includes vaccines, blood products, and diagnostic reagents, Sinopharm is renowned for its commitment to innovation and quality. The company has achieved significant milestones, such as being a key supplier of COVID-19 vaccines, which has bolstered its market position globally. Sinopharm's extensive distribution network and strong partnerships further enhance its reputation as a trusted provider in the healthcare sector, making it a cornerstone of China's pharmaceutical landscape.
DitchCarbon Score
How does Sinopharm Group Co. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinopharm Group Co. Ltd.'s score of 10 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sinopharm Group Co. Ltd.'s reported carbon emissions
In 2019, Sinopharm Group Co. Ltd. reported total carbon emissions of approximately 74,360,360 kg CO2e, comprising about 37,435,630 kg CO2e from Scope 1 and about 105,924,730 kg CO2e from Scope 2 emissions. In 2018, the company recorded total emissions of approximately 119,556,010 kg CO2e, with Scope 1 emissions at about 30,741,540 kg CO2e and Scope 2 emissions at about 88,611,470 kg CO2e. Despite these figures, Sinopharm has not publicly disclosed specific reduction targets or initiatives aimed at decreasing its carbon footprint. The absence of defined climate commitments or science-based targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. As a major player in the pharmaceutical industry, Sinopharm's emissions profile reflects the broader challenges faced by the sector in addressing climate change. The company’s commitment to improving its environmental impact will be crucial as global pressure mounts for businesses to adopt sustainable practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | |
|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 |
| Scope 2 | 88,611,470 | 000,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinopharm Group Co. Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
